Alimera Sciences Inc

Alimera Sciences — Technical Presentation (February 2011)

25 slides from Alimera Sciences's technical presentation, Feb 14, 2011

  1. Slide 1: FAME Study Fluocinolone Acetonide in Diabetic Macular Edema Month 36 Results

    FAME(tm) Study Fluocinolone Acetonide in Diabetic Macular Edema Month 36 Results Peter A. CampochiaroThe Wilmer Eye InstituteThe Johns Hopkins University School of MedicineBaltimore, MD

  2. Slide 2: Potential Conflicts of Interest

    Potential Conflicts of Interest The FAME(tm) Study is sponsored by Alimera Sciences Inc.Research Support Alimera Sciences Inc.GenentechGlaxoSmithKlineMolecular PartnersGenzymeOxford BioMedicaAlconConsulting AgreementsAllerganPfizerNovartisOraInstitutional Consulting Agreements GenentechGlaxoSmithKli

  3. Slide 3: ILUVIEN Drug Delivery Insert

    Non-bioerodable cylindrical tube 3.5 mm long, 0.37 mm in diameter Injected through a self sealing wound via 25-gauge proprietary inserter Two doses compared 0.2µg (Low Dose) and 0.5µg (High Dose) of fluocinolone acetonide (FAc) per day ILUVIEN(r) Drug Delivery Insert ILUVIEN(r) is a trademark of Ali

  4. Slide 4: Consistent and Low Daily Dosing

    Consistent and Low Daily Dosing in vitro Average Daily Wet Release Rates Human Aqueous Humor Levels(1) ILUVIEN is expected to deliver a sustained therapeutic effect over a 24 to 36 month period (1) Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, Ciulla T, Feiner L, Sabates N, Billma

  5. Slide 5: FAME Studies

    FAME Studies Two randomized, double-masked, parallel group, multicenter, dose-finding trialsDesigned to assess the safety and efficacy of 0.2 µg/d and 0.5 µg/d fluocinolone acetonide (FAC) intravitreal inserts vs sham injection in patients with DME Key Inclusion Criteria Age 18 years or olderDME wit

  6. Slide 6: FAME Study Design

    0 6 12 18 24 30 36 Low Dose (0.2 µg/d) High Dose (0.5 µg/d) Sham Control FAME Study Design Laser Allowed After Week 6* Retreatment any time after Month 12 (if eligible)** Study Ends Randomization 2:2:1 Primary Readout Subjects with DME and:^ 1 previous laserBCVA ^ 19 and ^ 68 letters (~20/50 to 20/4

  7. Slide 7: Baseline Characteristics and Demographics

    Baseline Characteristics and Demographics Baseline Characteristics and Demographics

  8. Slide 8: Baseline Visual Acuity and Foveal Thickness

    Baseline Visual Acuity and Foveal Thickness Baseline Visual Acuity and Foveal Thickness

  9. Slide 9: Patient Disposition

    Patient Disposition Patient Disposition

  10. Slide 10: Percentage of Patients With ≥15-Letter Improvement Over Baseline

    (CHART) Time (Months) Patients (%) 27.8% 28.7% 18.9% P = .018 Percentage of Patients With ^ 15-Letter Improvement Over Baseline Primary Readout 28.6% 28.7% 16.2% P = .002

  11. Slide 11: ≥15 Letter Increase in BCVA, Trials A&B Combined

    ^15 Letter increase in BCVA Trials A&B Combined Control(n = 185) 0.2 µg/d FAc(n = 376) p Value Percentage of Subjects Responding Percentage of Subjects Responding Month 24 16.2% 28.7% 0.002 Month 27 14.6% 28.7% <0.001 Month 30 15.1% 31.4% <0.001 Month 33 17.3% 29.0% 0.004 Month 36 18.9% 28.7% 0.018

  12. Slide 12: Mean Change From Baseline in BCVA Letter Score

    Mean Change From Baseline in BCVA Letter Score 0.5 µg/d FAc (n = 395) 0.2 µg/d FAc (n = 376) Control (n = 185) Months 2.0 5.3 5.3 P = .018 P = .007 Mean Change in BCVA Letter Score

  13. Slide 13: Time to Cataract AE

    Time to Cataract AEa a Phakic patients only. 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Time to Event (Months) 0 6 12 18 24 30 36 42 Probability of Event Control0.2 µg/d FAc0.5 µg/d FAc

  14. Slide 14: Time To Cataract Surgery

    Time To Cataract Surgery 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Probability of Event Time to Event (Months) 0 6 12 18 24 30 36 42 Control0.2 µg/d FAc0.5 µg/d FAc

  15. Slide 15: Mean BCVA Letter Change in 0.2 µg/d FAc Patients

    Months Pseudophakic (n = 140)Phakic (n = 48)Phakic ^ Pseudophakic (n = 188) Mean BCVA Letter Change in 0.2 µg/d FAc Patients Mean Change From Baseline in BCVA Letter Score

  16. Slide 16: Post-Cataract Surgery Visual Acuity Outcomes in ILUVIEN-Treated Patients vs Control

    Control (n = 32)0.2 µg/d FAc (n = 184) Control (n = 21)0.2 µg/d FAc (n = 136) BCVA, best-corrected visual acuity; FAc, fluocinolone acetonide. a Baseline represents the last visit prior to cataract surgery Post-Cataract Surgery Visual Acuity Outcomes in ILUVIEN-Treated Patients vs Control Baselinea

  17. Slide 17: Percentage of Patients With ≥15-Letter Improvement, Observed Cases

    Time (Months) Patients (%) 31.9% 33.0% 21.4% Percentage of Patients With ^ 15-Letter Improvement, Observed Cases Control 185 182 174 165 158 151 150 132 134 134 128 124 126 0.2 µg/d FAc 374 356 357 339 327 306 301 291 287 277 278 257 270 0.5 µg/d FAc 394 383 374 353 353 332 309 301 300 292 289 268 2

  18. Slide 18: Mean Change in BCVA Among Patients Who Completed 36-Month Assessment

    Time (Months) 7.1 8.1 3.2 Mean Change in BCVA Among Patients Who Completed the 36-Month Assessment Control 126 126 126 121 124 121 123 113 120 120 118 114 126 0.2 µg/d FAc 270 263 265 263 257 256 257 256 259 252 259 245 270 0.5 µg/d FAc 276 272 270 260 265 262 250 255 264 258 267 257 276 Patients, n

  19. Slide 19: Mean Center Point Retinal Thickness Over Time

    Mean Center Point Retinal Thickness Over Time (A + B) 280.0 µm 308.6 µm 299.9 µm Months Mean Center Point Thickness in Study Eye (µm) 0.5 µg/d FAc (n = 388) Control (n = 182) 0.2 µg/d FAc (n = 369) Difference in change from baseline vs controlP = .015 for 0.2 µg/d FAc P = .004 for 0.5 µg/d FAc

  20. Slide 20: Study, Laser, and Off-Protocol Treatments

    Study, Laser, and Off-Protocol Treatments Control(n = 185) 0.2 µg/d FAc(n = 376) 0.5 µg/d FAc(n = 395) Study Treatments (Sham injection or ILUVIEN device) Study Treatments (Sham injection or ILUVIEN device) Study Treatments (Sham injection or ILUVIEN device) Study Treatments (Sham injection or ILUVI

  21. Slide 21: ≥3-Step Improvement of Diabetic Retinopathy From Baseline

    ^ 3-Step Improvement of Diabetic Retinopathy From Baseline (ETDRS) Patients (%) Months

  22. Slide 22: Most Common Serious Ocular AEs

    Most Common Serious Ocular AEsa Most Common Serious Ocular AEsa ..a Events reported at ^ 1% either active arm, excluding cataract operation.

  23. Slide 23: Cataract-Related and IOP-Related Events

    Cataract-Related Events Cataract-Related Events a Phakic patients only.b For a minimum of 7 days. Subjects, %(Study Eye) Control(n = 185) 0.2 µg/d FAc (n = 375) 0.5 µg/d FAc(n = 393) IOP > 30 mm Hg 4.3 18.4 22.9 Any IOP-lowering medsb 14.1 38.4 47.3 Trabeculoplasty 0.0 1.3 2.5 Incisional IOP-lowerin

  24. Slide 24: Conclusions

    Conclusions ILUVIEN (0.2mcg/d) currently under review by the FDAEfficacyIn FAME A and B combined, 28.7% of ILUVIEN treated patients achieved ^15 letter gain at month 36 with peak effect of 31.4% at month 30, both statistically significantObserved cases response peaks at month 30 with 36% improving b

  25. Slide 25: Acknowledgments

    Acknowledgments The FAME Study Group956 Patients101 sites in North America, Europe and IndiaFundus Photograph Reading CenterEndothelial Cell Count Reading CenterCROs: Chiltern, EMMES, SIRO, CovanceAlimera Sciences Inc.pSivida Inc.

Alimera Sciences — Technical Presentation (February 2011) on 6ix